Funding opportunities related to COVID-19
NSF has encouraged submission of proposals related to Coronavirus Disease 2019 (COVID-19),
as described in the Dear Colleague Letter at
DUE is specifically interested in research on the impact of the COVID-19 outbreak on undergraduate education. The outbreak has altered undergraduate education in unforeseen ways, including forcing temporary closures and unplanned switches to online classes. DUE thinks that research about the impacts of such responses on students and educators could provide important new knowledge about STEM learning, virtual learning environments, the impact of stress on learning, and many other important topics.
If you are engaged in such research or would like to do so, we encourage you to consider submitting a proposal to any of our relevant funding programs including the Improving Undergraduate STEM Education (IUSE): EHR program, the IUSE:HSI program, the S-STEM program, the ATE program, the Noyce Program, and the ECR Core research program. (See https://www.nsf.gov/funding/programs.jsp?org=DUE)
Alternatively (or in addition), if you have an urgent research need or opportunity, you may consider submitting proposals via the following funding mechanisms:
1. Submit a Rapid Response Research (RAPID) proposal.
See Chapter II.E.1 of the NSF Proposal and Award Policies and Procedures Guide
2. Request supplemental support for your existing award.
See Chapter VI.E.4 of the NSF Proposal and Award Policies and Procedures Guide
3. Organize a conference or workshop.
See Chapter II.E.7 of the NSF Proposal and Award Policies and Procedures Guide
Possible topics of interest for these funding mechanisms include, but are not limited to, research on the effectiveness of switching from an in-person to a completely online educational format and research on how the outbreak affects student attitudes, interests, and performance in STEM.
Important: You should contact a program officer to explore whether your needs might be appropriate for funding via the RAPID, Supplemental Support, or Conference mechanisms. A list of DUE staff is available at https://www.nsf.gov/staff/staff_list.jsp?org=DUE&from_org=DUE.
NIAID is taking several approaches to support new research in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-2019).
Administrative Supplements for In-Scope Work
If you are a grantee currently supported by active NIH funding, you may be eligible to apply for an administrative supplement to support SARS-CoV-2/COVID-2019 research.
An administrative supplement is a noncompeting award that provides additional funding to a currently funded grant to meet increased costs that are within the scope of the approved project, but that were unforeseen when the new or competing renewal application was awarded.
Contact your program officer to discuss if this may be an option for you. If your proposed research on SARS-CoV-2/COVID-2019 is within the scope of your current grant, an administrative supplement is your best option to obtain additional funding. You’ll apply using the parent administrative supplement funding opportunity announcement (FOA): PA-18-591.
Medical Technology Enterprise Consortium (MTEC): The U.S. Army is seeking medical and information technologies to combat COVID-19
The Medical Technology Enterprise Consortium (MTEC) released a pre-announcement on a potential RFP for prototypes of medical and information technologies to combat COVID-19. The U.S. Army is seeking medical and information technologies which can be deployed by 31 Dec in the following areas:
- Point-of-care diagnostic that provides rapid and accurate confirmation of exposure to Covid-19.
- Prophylactics and therapeutics that can prevent and/or treat patients within a few hours to two days, potentially in a non-hospital environment. The consortium would prefer to repurpose FDA-approved drugs and/or biologics or test those that have already safely demonstrated.
- Disease predictive modeling based on different data streams—including social media and artificial intelligence—that provides early warning to the government and medical service providers.
- Patient monitoring, tracking, and management system for in-home or non-hospital tele-health services that can also connect to the Cerner electronic health record.
If the Army does release a formal solicitation, the RPP will be posted to the MTEC website, likely within the next few weeks. The MTEC will use an enhanced white paper contracting process, similar to what has been used by other consortia with the intent of awarding contracts rapidly. After the RPP is released, offerors will then be required to submit their enhanced white papers within two weeks. The papers should include an abbreviated technical approach, detailed statement of work, and an estimate of cost. Several offerors may be invited for informal discussions with the government. Offerors who are recommended for award will be required to submit a full cost proposal. Awards could be issued within four to six weeks of the RPP release date.
MTEC membership is not required for the submission of white papers, though will be required for award. According to their website, USF is not currently a member so if accepted for award, you would need to pursue joining. Since FY 2016 the Army and the Navy have invested $162.4 million via MTEC. This consortium is an internationally dispersed group of industry, academia and nonprofits members funded under an OTA with the U.S. Army Medical Research and Development Command (USAMRDC). Their purpose is to accelerate the development of medical solutions that prevent / treat injuries of U.S. soldiers. Even if not selected for an award, it may make sense to join for future notifications / opportunities and networking engagement among other members.
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Notice Number: NOT-DA-20-047
Release Date: March 19, 2020
First Available Due Date: March 19, 2020
Expiration Date: March 31, 2021
PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent
Supplement - Clinical Trial Optional)
PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
National Institute on Drug Abuse (NIDA)
NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.
As people across the U.S. and the rest of the world prepare for what could be a pandemic of the 2019 novel coronavirus, or COVID-19, the research community should be alert to the possibility that it could affect some populations with substance use disorders or HIV particularly hard. Because it attacks the lungs, COVID-19 could be an especially serious threat to those with histories of smoking tobacco or marijuana or of vaping. People who use opioids or methamphetamine may also be vulnerable due to those drugs’ effects on respiratory and pulmonary health and potential effects on immune mechanisms. Likewise, those with HIV may be affected if their immune function is compromised. Additional social and environmental factors associated with drug use may worsen the transmission and treatment of COVID-19, especially among individuals who experience homelessness or incarceration, which is more common among those with a substance use disorder.
In order to rapidly improve our understanding of the risks, prevalence, and available control measures for 2019-nCoV in substance using or HIV-affected populations, NIDA is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:
- Research to determine whether substance use (especially smoking tobacco or marijuana, vaping, opioids and other drug use) is a risk factor for the onset and progression of COVID-19.
- Research on how HIV among persons who use substances may impact the onset and progression of COVID-19.
- Research to understand system-level responses to COVID-19 prevention and risk mitigation
in secure settings such as prisons and jails, with a particular emphasis on detainees
with substance use disorder (SUD). For example:
- Interactions of COVID-19 treatment with SUD treatments, including medications for opioid use disorders
- Strategies for integrating COVID-19 and other infectious disease screening, prevention, and treatment protocols with SUD treatment and other health services.
- Research to understand the respiratory effects of SARS-CoV-2 infection among individuals with substance use disorders (SUD); in particular those with nicotine, marijuana, opioid, and methamphetamine use disorders.
- Research to understand how the respiratory effects of COVID-19 influences the rate of opioid overdoses both in pain patients as well as patients with an opioid use disorders and also to assess how it influences the outcomes for naloxone interventions for overdose reversal
- Research to develop therapeutic approaches for comorbid SARS-CoV-2 infection and SUDs.
Research to evaluate drug-drug interaction of medications to treat SARS-CoV-2 and substances of abuse or medications to treat SUDs.
- Research to understand system- or organizational-level responses to identify, prevent, or mitigate the impact of COVID-19 in service settings that serve vulnerable populations, including people who are homeless or unstably housed.
- Research to understand and mitigate the impact of COVID-19 in methadone treatment programs and syringe exchange services.
- Research on how potential overcrowding of emergency departments and health services will impact the treatment of opioid overdoses and of opioid use disorder
- Research using ongoing studies to understand the broad impacts of COVID-19 (e.g., school closures, food insecurity, anxiety, social isolation, family loss) on neurodevelopment, substance use, substance use disorders, and access to addiction treatment.